CRMD Share Price Performance
US$7.98
7.98 (0.00%)
33.5% undervalued intrinsic discount
US$12.00
Fair Value
Price US$7.98
MRT23 US$12.00
AnalystConsensusTarget US$15.00
AnalystHighTarget US$22.00
Fair ValueUS$12.00
Share Pricen/a
CorMedix Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 103 Fair Values set on narratives written by author
CRMD Community Narratives
MR
Fair Value
·Fair Value US$12 33.5% undervalued intrinsic discount
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value
·Fair Value US$15 46.8% undervalued intrinsic discount
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
0users have liked this narrative
0users have commented on this narrative
35users have followed this narrative
AN
Fair Value
·Fair Value US$22 63.7% undervalued intrinsic discount
Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
This company’s main dialysis infection product still looks hard to replace, but the market seems to be pricing it as if growth has stalled for good. A pricing change and two upcoming trial readouts could reshape the story quickly, with big upside if things go right—and a clear hit if they don’t.Read more
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
Key Takeaways Acquisition and integration efforts diversify revenue streams and improve operational efficiency, supporting stronger earnings and margin growth. Expanded pipeline and portfolio address rising demand in infection control, enhancing market penetration and supporting long-term profitability.Read more
AN
US$15
46.8% undervalued intrinsic discount
Fair Value
Revenue
4.25% p.a.
Profit Margin
19.19%
Future PE
26.11x
Price in 2029
US$14.14
Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside
Catalysts About CorMedix CorMedix develops and commercializes specialty therapies that prevent and treat life threatening infections in high risk hospital and clinic patients. What are the underlying business or industry changes driving this perspective?Read more
AN
US$14
43.0% undervalued intrinsic discount
Fair Value
Revenue
12.31% p.a.
Profit Margin
20.89%
Future PE
26.07x
Price in 2028
US$11.88
Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership
Catalysts About CorMedix CorMedix develops and commercializes differentiated therapies that prevent and treat serious, life-threatening infections in acute care settings. What are the underlying business or industry changes driving this perspective?Read more
AN
US$22
63.7% undervalued intrinsic discount
Fair Value
Revenue
38.37% p.a.
Profit Margin
52.62%
Future PE
8.7x
Price in 2028
US$18.67
Trending Discussion
Recently Updated Narratives
MR
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
Fair Value: US$12 33.5% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CRMD: Mixed Research And Phase III Success Will Support Undervalued Shares
Fair Value: US$15 46.8% undervalued intrinsic discount
35 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside
Fair Value: US$14 43.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CorMedix Inc. Key Details
About CRMD
- Founded
- 2006
- Employees
- 191
- CEO
- WebsiteView website
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
